Press esc to close search
Our education section provides in-depth guides and articles across a range of topics.
Our glossary is a great place to start if you’re new to the world of investing.
Pharmaceuticals
Roche (RHHBY): Significant U.S. Investment to Enhance Manufacturing and Innovation
Roche plans to invest $50 billion in the U.S., creating over 12,000 jobs and expanding its manufacturing and R&D capabilities.
Eli Lilly and Co (NYSE:LLY): Promising Breakthrough in Weight-Loss Treatments
Eli Lilly's orforglipron shows promise as a weight-loss pill, boosting shares by 12% and marking a major milestone in diabetes treatment.
Healthcare Disruptors: AI, Telehealth and Cost Savings
UnitedHealth, Elevance Health, Cigna, and Medicus Pharma are driving AI, telehealth, and value-based care to transform patient outcomes and cost efficiency.
Johnson & Johnson Stock (JNJ): Leading the Lung Cancer Treatment Race
J&J's lung cancer therapy outshines AstraZeneca's, but upcoming data from Astra could change market dynamics.
Healthcare Climbs as Tech Stumbles in 2025 Shift
Not all corners of the market are moving in the same direction this year. 2025 has already delivered a few surprises for sector-focused investors.
While Big Pharma Stalls, One Small-Cap Breaks Out
The market’s focus is narrow, but step outside the spotlight, and you’ll find where real momentum is building.
23andMe (NASDAQ: ME): Bankruptcy Filing and Strategic Sale Process
23andMe has filed for Chapter 11 to maximize business value while facing a steep decline, leadership change, and investment risks surrounding genetics.
Alnylam Pharmaceuticals Stock (ALNY): Innovative Treatment for ATTR Amyloidosis
Alnylam Pharmaceuticals gains FDA approval for AMVUTTRA, marking a milestone in the fight against ATTR amyloidosis with effective treatment options.
3 US Healthcare Stocks That Might Be Undervalued 2025
Healthcare is showing strength in a shaky market—discover which overlooked U.S. stocks could potentially offer upside as the sector regains investor attention.
Medicus Pharma Share Price: MDCX Stock Closed Up 15.35%
Medicus Pharma Share Price Soars: Medicus Pharma closed yesterday at $3.4950, up 15.35% from the previous close of $3.03. Find out all you need to know.
Advancing Oncology: Innovations in Treatment and Detection
Oncology is advancing with AI, biologics, and non-invasive treatments. See how AstraZeneca, Roche, AbbVie, and Medicus Pharma are leading the way.
See Why Some Investors Are Watching This Biotech Company
Innovation in healthcare is not just about science. It’s also about the patient experience. One small company is developing a unique treatment.
Haleon (HLN): Pfizer Sells Stake in Consumer Healthcare Firm
Pfizer has finalized its exit from Haleon by selling its remaining stake for £2.5 billion, marking a significant milestone for the firm.
Gilead Sciences (GILD): Potential Impact of Federal HIV Funding Cuts
Gilead Sciences shares fall amid reports of potential federal funding cuts for HIV initiatives, raising concerns for investors.
Biotech Stock Tapping $7B+ Skin Cancer Market Opportunity
Medicus Pharma (NASDAQ: MDCX) is revolutionizing skin cancer treatment with a non-invasive microneedle patch, tapping into a $7B market opportunity. Discover more.